

# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Kerendia Clinical Edit
<b>First Implementation Date:</b>	TBD
<b>Proposed Date:</b>	December 16, 2021
<b>Prepared for:</b>	MO HealthNet
<b>Prepared by:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input checked="" type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** Ensure appropriate utilization and control of Kerendia® (finerenone).

**Why Issue Selected:** Kerendia® (finerenone) was approved by the FDA on July 9, 2021 to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). CKD is defined as abnormalities of kidney structure or function, present for at least 3 months, with implications for health. CKD is classified into stages, ranging from Stage 1 (early disease) to Stage 5 (end-stage disease with complete kidney failure). 37 million (15%) adults in the United States (U.S.) have been diagnosed with CKD; approximately 8 million of which have Stage 1-4 CKD in addition to T2D. Kerendia is a nonsteroidal, selective mineralocorticoid receptor antagonist (MRA). Kerendia has a high potency and selectivity for the mineralocorticoid receptor (MR) and has no relevant affinity for androgen, progesterone, estrogen, and glucocorticoid receptors. MR overactivation is thought to contribute to fibrosis and inflammation in the kidneys and cardiovascular system. MR selectivity differentiates Kerendia from other available aldosterone antagonists (i.e., spironolactone or eplerenone) and may result in lower incidence of adverse effects.

Due to the specific approved indication, MO HealthNet will impose clinical criteria to ensure appropriate utilization of Kerendia.

Program-Specific Information:	Date Range FFS 10-01-2020 to 9-30-2021				
	Drug	Claims	Cost per tablet	Cost per month	Cost per year
	KERENDIA 10 MG TABLET	1	\$18.97	\$569.10	\$6,924.05
	KERENDIA 20 MG TABLET	0			

**Type of Criteria:**  Increased risk of ADE  Preferred Drug List  
 Appropriate Indications  Clinical Edit

**Data Sources:**  Only Administrative Databases  Databases + Prescriber-Supplied

## Setting & Population

- Drug class for review: Kerendia® (finerenone)
- Age range: All appropriate MO HealthNet participants aged 18 years or older

## Approval Criteria

- Documentation of compliance to previous Kerendia therapy (90/120 days) **OR**
- Participant is aged  $\geq$  18 years **AND**
- Documented diagnosis of CKD stage 1-4 **AND**
- Documented diagnosis of type 2 diabetes **AND**
- Documented therapy with ACE-inhibitor (ACEI) or angiotensin receptor blocker (ARB) for 60 of the past 90 days **AND**
- Documented adequate therapeutic trial of 2 sodium-glucose co-transporter 2 (SGLT2) inhibitors

## Denial Criteria

- Therapy will be denied if all approval criteria are not met
- Participant is currently pregnant
- Diagnosis of adrenal insufficiency
- Diagnosis of CKD stage 5 or end stage renal disease
- Claim is for more than 1 tablet per day

## Required Documentation

Laboratory Results:  
MedWatch Form:

  

Progress Notes:  
Other:

  

## Disposition of Edit

Denial: Exception code "0682" (Clinical Edit)  
Rule Type: CE

## Default Approval Period

3 months

## References

- Kerendia® (finerenone) [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; July 2021.
- IPD Analytics. Renal: Chronic Kidney Disease. Available at: <https://secure.ipdanalytics.com/>. Accessed November 2021.
- KDIGO 2012 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1). Available at: <https://kdigo.org/guidelines/ckd-evaluation-and-management/>. Accessed November 2021.
- de Boer IH, Caramori ML, Chan JCN, et al. Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. Kidney Int 2020; 98:839–848. Available at: <https://kdigo.org/wp-content/uploads/2018/03/KDIGO-Diabetes-in-CKD-GL-Exec-Summary.pdf>. Accessed November 2021.

*SmartPA Clinical Proposal Form*

© 2021 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

- Bakris GL, Agarwal R, Anker SD, et al., on behalf of the FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020; 383:2219-29. Available at: <https://www.nejm.org/doi/full/10.1056/NEJMoa2025845>. Accessed November 2021.
- Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal mineralcorticoid receptor antagonists in cardiorenal medicine. Eur H J 2021; 42:152-161. Available at: <https://academic.oup.com/eurheartj/article/42/2/152/5936792>. Accessed November 2021.
- ClinicalTrials.gov. U.S. National Library of Medicine. Available at: <https://www.clinicaltrials.gov/ct2/home>. Accessed November 2021.
- IPD Analytics. New Drug Review: Kerendia (finerenone). August 2021.

DRAFT

*SmartPA Clinical Proposal Form*

© 2021 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.